Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection
| Autor: | Lay Lay Win, David Wong, Paul A. James |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Genotype Physiology Viremia HIV Infections Hepacivirus Antiviral Agents chemistry.chemical_compound Pegylated interferon Internal medicine Ribavirin medicine Humans Immunodeficiency Retrospective Studies business.industry Coinfection Gastroenterology virus diseases Hepatitis C Hepatology Hepatitis C Chronic Middle Aged medicine.disease Virology chemistry Female Interferons business medicine.drug |
| Zdroj: | Digestive diseases and sciences. 59(8) |
| ISSN: | 1573-2568 |
| Popis: | Current guidelines recommend that interferon-based treatment of hepatitis C (HCV) genotype 2 or 3 in those with HIV coinfection should be for 48 weeks, especially if HCV PCR remains positive after 4 weeks of treatment. To examine a single-center experience using response-guided therapy (RGT) using pegylated interferon (PegIFN) and weight-based ribavirin (RBV) for treating HCV genotype 2 or 3 in those with HIV coinfection. Electronic medical records were used to identify patients with HCV genotype 2 or 3 HIV coinfection seen at the Toronto General Hospital Immunodeficiency Clinic from February 2003 to December 2012. HCV PCR was tested after every 4 weeks of treatment until it was negative ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink